Lin Kimberly Y, Kerur Basavaraj, Witmer Char M, Beslow Lauren A, Licht Daniel J, Ichord Rebecca N, Kaufman Beth D
1Division of Cardiology,Department of Pediatrics,Children's Hospital of Philadelphia, Perelman School of Medicine at theUniversity Pennsylvania,Philadelphia,Pennsylvania,United States of America.
2Department of Pediatrics,Albert Einstein Medical Center,Philadelphia,Pennsylvania,United States of America.
Cardiol Young. 2014 Oct;24(5):840-7. doi: 10.1017/S1047951113001145. Epub 2013 Sep 9.
Children with myocarditis have multiple risk factors for thrombotic events, yet the role of antithrombotic therapy is unclear in this population. We hypothesised that thrombotic events in critically ill children with myocarditis are common and that children with myocarditis are at higher risk for thrombotic events than children with non-inflammatory dilated cardiomyopathy.
This is a retrospective chart review of all children presenting to a single centre cardiac intensive care unit with myocarditis from 1995 to 2008. A comparison group of children with dilated cardiomyopathy was also examined. Antithrombotic regimens were recorded. The primary outcome of thrombotic events included intracardiac clots and any thromboembolic events.
Out of 45 cases with myocarditis, 40% were biopsy-proven, 24% viral polymerase chain reaction-supported, and 36% diagnosed based on high clinical suspicion. There were two (4.4%) thrombotic events in the myocarditis group and three (6.7%) in the dilated cardiomyopathy group (p = 1.0). Neither the use of any antiplatelet or anticoagulation therapy, use of intravenous immune globulin, presence of any arrhythmia, nor need for mechanical circulatory support were predictive of thrombotic events in the myocarditis, dilated cardiomyopathy, or combined groups.
Thrombotic events in critically ill children with myocarditis and dilated cardiomyopathy occurred in 6% of the combined cohort. There was no difference in thrombotic events between inflammatory and non-inflammatory cardiomyopathy groups, suggesting that the decision to use antithrombotic prophylaxis should be based on factors other than the underlying aetiology of a child's acute decompensated heart failure.
心肌炎患儿存在多种血栓形成事件的风险因素,但抗血栓治疗在该人群中的作用尚不清楚。我们假设,患有心肌炎的危重症患儿血栓形成事件很常见,且心肌炎患儿发生血栓形成事件的风险高于非炎性扩张型心肌病患儿。
这是一项对1995年至2008年在单一中心心脏重症监护病房就诊的所有心肌炎患儿的回顾性病历审查。还检查了一组扩张型心肌病患儿作为对照组。记录抗血栓治疗方案。血栓形成事件的主要结局包括心内血栓和任何血栓栓塞事件。
在45例心肌炎病例中,40%经活检证实,24%有病毒聚合酶链反应支持,36%根据高度临床怀疑确诊。心肌炎组有2例(4.4%)发生血栓形成事件,扩张型心肌病组有3例(6.7%)(p = 1.0)。在心肌炎组、扩张型心肌病组或合并组中,使用任何抗血小板或抗凝治疗、使用静脉注射免疫球蛋白、存在任何心律失常以及是否需要机械循环支持均不能预测血栓形成事件。
患有心肌炎和扩张型心肌病的危重症患儿中,6%的合并队列发生了血栓形成事件。炎性和非炎性心肌病组之间血栓形成事件无差异,这表明抗血栓预防的决策应基于儿童急性失代偿性心力衰竭潜在病因以外的因素。